申请人:Dokou Eleni
公开号:US20100081642A1
公开(公告)日:2010-04-01
The present invention relates to pharmaceutical compositions that stabilize and improve the bioavailability of 3-[(1S)- 1-(1-(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile. In particular, the present invention relates to pharmaceutical compositions that include 3-[(1S)-1-(1-(S)-(4-chlorophenyl)[3 -(5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile and at least one pharmaceutical acceptable excipient, such as a mono-, di- or triglyceride.
本发明涉及稳定并改善3-[(1S)-1-(1-(S)-(4-氯苯基)[3-(5-氧代-4,5-二氢-1,3,4-噁二唑-2-基)苯基]甲基}氮杂环己烷-3-基)-2-氟-2-甲基丙基]-5-氟苯甲腈的药物组合物。具体而言,本发明涉及包括3-[(1S)-1-(1-(S)-(4-氯苯基)[3-(5-氧代-4,5-二氢-1,3,4-噁二唑-2-基)苯基]甲基}氮杂环己烷-3-基)-2-氟-2-甲基丙基]-5-氟苯甲腈和至少一种药用可接受的赋形剂的药物组合物。